Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-WHO defends data after concluding Gilead's remdesivir flopped COVID trial

Fri, 16th Oct 2020 11:43

(Adds details, background)

ZURICH/GENEVA, Oct 16 (Reuters) - A World Health
Organization (WHO) trial that concluded Gilead Sciences Inc.'s
remdesivir did not significantly help COVID-19 patients
is reliable, a scientist who evaluated the data said on Friday,
as the U.S. company criticized its methodology.

"It's a reliable result, don't let anybody tell you
otherwise, because they'll try to," Richard Peto, an independent
statistician hired by the WHO to scrutinize its Solidarity trial
results, told reporters. "This is real world evidence."

In a blow to one of the few drugs being used to treat people
with COVID-19, the WHO said on Thursday that remdesivir appeared
to have little or no effect on 28-day mortality or length of
hospital stays among patients with the respiratory
disease.

Gilead, which got the Solidarity data 10 days ago,
questioned the findings, telling Reuters they appear
"inconsistent with more robust evidence from multiple
randomized, controlled studies published in peer-reviewed
journals validating the clinical benefit of remdesivir."

The WHO trial was conducted in 11,266 adult patients in more
than 30 countries, and also found that other medicines
repurposed since the pandemic began -- malaria drug
hydroxychloroquine, anti-HIV drug combination
lopinavir/ritonavir and interferon -- also offered little or no
benefit to COVID-19 patients.

The WHO trial's results are yet to be reviewed and were
uploaded on the preprint server medRxiv. (https://bit.ly/3nViYIf)

While Gilead said other remdesivir trials, including with
1,062 patients that compared it with a placebo, showed the
treatment cut COVID-19 recovery time, Peto, a professor emeritus
at Oxford University, said the smaller trial's perceived benefit
could have been mere "chance."

The WHO refrained from making a recommendation for how
countries should deploy remdesivir, saying that guidance would
come in two or three weeks after a review of Solidarity data.
The European Union just agreed to a 1 billion euros ($1.2
billion) deal for remdesivir.
($1 = 0.8535 euros)
(Reporting by John Miller and Stephanie Nebehay;)

More News

UPDATE 1-Pound, gilt yields up as BoE flags economic rebound, slower bond-buys

* BoE slows bond-buying but hikes growth forecast* Sterling falls then rebounds* 'Super Thursday' elections see Scots head to polls* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh* Graphic: Trade-weighted sterling since Brexit vote http://t...

Today 12:53

TOP NEWS: Bank of England votes unanimously to keep interest rates low

TOP NEWS: Bank of England votes unanimously to keep interest rates low

Today 12:37

UPDATE 1-UK working with U.S., WTO on boosting COVID vaccine supply

(Adds detail)LONDON, May 6 (Reuters) - Britain is discussing ways of increasing production and supply of COVID-19 vaccines with the United States and World Trade Organization, a government spokesperson said on Thursday after Washington supported w...

Today 12:32

Zambeef shares jump after raising profit expectations by up to 30%

Zambeef shares jump after raising profit expectations by up to 30%

Today 12:18

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.